RENAL CELL CARCINOMA (RCC)

This study tests a new drug called zanzalintinib, alone or with other immune-boosting drugs, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find safe doses and see if the combination can shrink tumors or slow their growth.…

This study tests whether the immunotherapy drug toripalimab can prevent kidney cancer from coming back in high-risk patients who have had their kidney removed. Researchers will also check if a blood test for minimal residual disease (MRD) can predict which patients benefit most. …

This study tests a new robotic surgery technique for kidney cancer that avoids clamping blood vessels and using stitches to close the kidney. The goal is to preserve as much kidney function as possible and reduce the risk of long-term kidney disease. About 59 adults with small ki…

This early-stage trial tests an experimental drug called CTX-10726 in about 70 people with advanced gastroesophageal, liver, endometrial, or kidney cancers that have stopped responding to standard treatments. The main goal is to check safety and find the right dose. Participants …

This study tests whether adding tivozanib to the standard immunotherapy pembrolizumab works better than pembrolizumab alone to keep kidney cancer from returning after surgery. About 1040 adults with high-risk clear cell renal cell carcinoma will take part. The goal is to see if t…

This Phase 2 trial tests an oral drug called veonetinib (AL8326) in 80 adults with advanced small cell lung cancer, non-small cell lung cancer, or renal cell carcinoma who have already tried at least one prior treatment. The study aims to find the best dose and see if the drug ca…

This study tests a new way to deliver radiation to kidney tumors using advanced imaging to better target the cancer while avoiding healthy tissue. About 40 adults with non-spread kidney cancer will receive this tailored radiotherapy. The goal is to reduce damage to the kidney and…

This phase 3 trial tests a drug called 177Lu-TLX250, which delivers radiation directly to kidney cancer cells. It is for adults with advanced clear cell kidney cancer that has returned or spread after prior treatments. The study first finds the best dose, then compares it to stan…

This study tests whether taking cabozantinib in a pattern that skips some days can keep the same drug levels in the body as the standard daily dose. It involves 34 adults with advanced kidney cancer who are already on a stable dose. Participants will try both the standard and the…

This early-phase trial tests a new drug called Sapu003, given with or without exemestane, in adults with advanced cancers that respond to mTOR pathways—including certain breast, kidney, liver, and neuroendocrine tumors. The main goal is to find the safest dose and check for side …

This early-phase study tests a new drug called LB-LR1109 in people with advanced solid tumors like lung, kidney, head and neck, bladder, or skin cancer that has not responded to standard treatments. The study first gives the drug alone, then in combination with another cancer dru…

This early-stage trial tests a new type of immunotherapy called CD70-targeted CAR-T cells in people with advanced solid tumors, including kidney, lung, ovarian, and thyroid cancers. The treatment involves taking a patient's own immune cells, engineering them to recognize and atta…

This phase 2 trial tests a three-part approach for advanced kidney cancer: first, a procedure to block blood flow to the tumor, then two drugs (toripalimab and axitinib) before surgery, followed by more toripalimab after surgery. The goal is to see if this makes surgery more succ…

This phase 2 trial is testing whether PET/CT scans can safely guide treatment pauses in people with advanced kidney cancer. Participants who have responded well to at least 12 months of standard therapy (immunotherapy plus targeted drugs) will stop treatment and be monitored with…

This study tests a new drug called GI-108 in people with advanced or metastatic solid tumors, including lung, head and neck, pancreatic, and kidney cancers. The drug is designed to boost the immune system's ability to fight cancer. The trial will first find the safest dose, then …

This study compares two ways to remove a kidney: laparoscopic (keyhole) surgery and open surgery. Researchers will look at how long patients stay in the hospital, blood loss, complications, and costs. The study includes 60 adults with a nonfunctioning kidney or early-stage kidney…

This study looks at the immune cells in the lymph nodes near kidney tumors to learn how the body fights the cancer. Researchers will analyze tissue samples from 10 adult kidney cancer patients to find clues about why some treatments work and others don't. The goal is to discover …

This study uses data from 4,700 kidney cancer patients treated at a single hospital over 12 years. The goal is to create a new model that better predicts how the disease will progress, especially for patients with a tumor thrombus. Researchers will also test whether using this mo…